Oppenheimer Reiterates Outperform on Odyssey Therapeutics, Maintains $40 Price Target

Benzinga Newsdesk www.benzinga.com Negative 82.2%

Neg 82.2% Neu 0% Pos 0%

Oppenheimer analyst Jeff Jones reiterates Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform and maintains $40 price target.